Sequenom Inc.'s lab in California aims to develop early diagnostic testing for macular degeneration, then may pass completion of the test's development to its Grand Rapids laboratory.
According to excerpts from the story:
Licensing the rights to develop a genetic diagnostic test for an eye disease that can lead to blindness means more work for Sequenom Inc.'s lab in Grand Rapids.
The San Diego-based Sequenom today said it has signed a global licensing deal to use intellectual property developed by Optherion Inc. in New Haven, Conn., to develop a genetic test for late stage age-related macular degeneration.
The company will conduct early development of the new diagnostic test in San Diego and transition the work later this year to its Sequenom Center for Molecular Medicine lab in Grand Rapids.
Read the complete story
here.
Enjoy this story?
Sign up for free solutions-based reporting in your inbox each week.